Impressive Bleeding Profile With Factor XI Inhibitor in AF


Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.
Medscape Medical News

Articles You May Like

How Peripheral Artery Disease Can Sneak Up on You
Chicago scrambles to house migrants with cold weather ahead
Artificial intelligence can be a useful workforce tool
iBuyers: The Benefits for Sellers and Real Estate Investors
Best Lego Deals: Save on Star Wars, Marvel, and Technic Sets | Digital Trends